Ciro Celsa
@CiroCelsa
Followers
286
Following
714
Media
35
Statuses
267
Gastroenterologist and Hepatologist. #Researcher at @unipa_it University of Palermo, Italy. @PROMISE_Unipa. #ResearchFellow at @ImperialCollege. Pianist.
Joined May 2014
Happy to share the results of this great international effort with @DJPinato. DT-Real study now published on @JHEP_Reports @PROMISE_UNIPA @unipa_it @imperialcollege
STRIDE preserves efficacy outside HIMALAYA - 🕵️♂️the first and largest cohort of D+T treated patients now on @JHEP_Reports / DT-Real @CiroCelsa
https://t.co/GJZZNcvW0K
0
2
6
Liver cancer care has evolved from limited options to therapies that help patients live longer. 🩺 In this video, @DJPinato explores how #immunotherapy and collaboration are changing outcomes, with hope and responsibility at the core. Watch & share! #LiverCancerAwarenessMonth.
0
6
9
Please have a look at our editorial published in #ASCODailyNews
@A_DAlessioMD @CiroCelsa @StephenLChan1 #IakovBolnykh
@ASCO @HUNIMED @HumanitasMilano From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma
dailynews.ascopubs.org
The treatment landscape for unresectable hepatocellular carcinoma has undergone profound change over the past 5 years, presenting both unprecedented opportunities and complex decision-making challe...
0
8
22
A great honour to receive @myESMO Merit Award for our abstract on the use of large language models in #HCC at #ESMOAI25 in collaboration with @m_giuffre @unipa_it @PROMISE_UNIPA
👏👏👏 Congratulations to the #ESMOMeritAward recipients on their abstracts submitted at #ESMOAI25, which demonstrated outstanding scientific merit.
0
0
3
🚨 New in @JHepatology:~20% of pivotal HCC phase III RCT face non-proportional hazards, mainly in ICI-based regimens. We propose robust tools (MaxCombo, RMST, pHR) + maturity rules to avoid premature stops.✅ FDA now adopts these same parameters.@EASLnews
journal-of-hepatology.eu
Non-proportional hazards (NPH) can lead to discrepancies between interim (IA) and final analyses (FA) in randomized controlled trials (RCTs) of hepatocellular carcinoma (HCC). We assessed the impact...
2
4
13
Are hepatic and extrahepatic outcomes different in MetALD vs MASLD? Our meta-analysis now online on @LancetGastroHep shows MetALD associated with ⬆️ risk of ✓ Liver-related events ✓ #HCC ✓ Extrahepatic cancers Tailored approaches for #MetALD are needed
1
1
3
Meta-analysis showed atezolizumab+bevacizumab most favorably balances OS and QoL for HCC. The combo reduces deterioration in global health, abdominal swelling, jaundice, pain vs sorafenib. @DJPinato
https://t.co/TLeNomKDAP
#HCC #Immunotherapy
3
4
13
Atezolizumab plus bevacizumab optimally balances quality of life preservation and survival benefits for patients with unresectable or advanced hepatocellular carcinoma. https://t.co/jQ7trAr6St
1
22
55
Quality of life matters in #HCC! Read our last network meta-analysis now online on @JAMAOnc @DJPinato @cabibbo78 @A_DAlessioMD @FulgenziClaudia @BeStef33 @gfmanfredi @paslombardi
jamanetwork.com
This network meta-analysis compares the health-related quality-of-life effects of different first-line treatments for unresectable or advanced hepatocellular carcinoma while considering treatment-i...
1
7
13
Hepatic decompensation (HD) is a critical survival determinant in patients with HCC under systemic therapy and strategies for recompensation are urgently warranted RCTs should incorporate HD as a relevant endpoint https://t.co/Au8tWWeAFb
@DJPinato @CiroCelsa @ReibergerThomas
journal-of-hepatology.eu
Unlike other solid tumours, the prognosis of patients with advanced hepatocellular carcinoma (HCC) is dually influenced by tumour progression and liver dysfunction. Accumulating evidence suggests...
1
3
5
Deeply honored to receive the Emerging Talent in #Hepatology award with friends and colleagues @FedRavaioli @AlessioGerussi @FrancescaRatti3 in a stunning venue in Bologna. Special thanks to Prof. @FabioPiscaglia and Prof. Invernizzi for this recognition @PROMISE_UNIPA @unipa_it
2
0
10
Read the #GUTOnline paper by @CiroCelsa et al on "Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies" via https://t.co/WGVVr4y5Ph In a meta-analysis of 11 cohort
0
6
5
📣Now online our new study on #GLP1RA and liver outcomes!🔬 GLP-1 agonists reduce risk of major adverse liver outcomes in T2 diabetes pts. Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC #LiverTwitter
1
6
19
In Focused Communications, Rizzo et al focus on "EUS-guided transesophageal fine-needle biopsy sampling of lung masses: diagnostic performance and safety." https://t.co/RxaVQb4IGr
#GITwitter #GIEJournal
@BilalMohammadMD
0
5
8
🤔Need for dedicated non-invasive tests in pts with chronic cholestatic diseases?
0
0
1
In press on @AGA_CGH our multicenter study 🇮🇹 🇬🇧 on 293 pts with PBC 🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe. 👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria @VincenzaCalvar1 @MCarbone_80
https://t.co/r4HVAlgj21
1
11
28